RNAC - Cartesian Therapeutics Inc

9.02
2.170   24.058%

Share volume: 2,923,114
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.20%

PREVIOUS CLOSE
CHG
CHG%
$6.85
2.17
0.32%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 49%
Dept financing 42%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
31.10%
1 Month
39.41%
3 Months
14.90%
6 Months
-8.05%
1 Year
-49.64%
2 Year
-52.95%
Key data
Stock price
$9.02
P/E Ratio 
0.00
DAY RANGE
$6.55 - $9.16
EPS 
-$1.90
52 WEEK RANGE
$5.98 - $18.55
52 WEEK CHANGE
-$50.06
MARKET CAP 
265.741 M
YIELD 
N/A
SHARES OUTSTANDING 
26.004 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$603,730
AVERAGE 30 VOLUME 
$274,095
Company detail
CEO: Carsten Brunn
Region: US
Website: www.cartesiantherapeutics.com
Employees: 64
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.

Recent news